BridgeBio Signs Technology Licensing Agreement for Pulmonary Fibrosis Treatment Candidate
[Asia Economy Reporter Kwon Jaehee] BridgeBio announced on the 19th that it has signed a technology licensing agreement for a candidate drug for idiopathic pulmonary fibrosis (IPF) treatment with Shaperon Co., Ltd.
Hot Picks Today
!["Stock Set to Double: This Company Smiles Every Time a Data Center Is Built [Click e-Stock]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026050416112750184_1777878687.jpg)
"Stock Set to Double: This Company Smiles Every...
- "Is Yours Just Gathering Dust at Home? Millennials & Gen Z Rediscover Digicams O...
- "Continuous Groundwater Pumping Causes Mexico City to Sink 24cm Annually... 'Gia...
- "I Take Full Responsibility"... Seongjae Ahn Issues Direct Apology for 'Wine Swi...
- “She Shouted, ‘The Rope Isn’t Tied!’... Chinese Woman Falls from 168m Cliff ...
The contract amount includes an upfront payment of 2 billion KRW and a milestone technology fee of 28 billion KRW.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
